Clark, CourtneyBarzegar Behrooz, AmirCordani, MarcoShojaei, ShahlaGhavami, SaeidTurksen, Kursad2025-05-052025-05-052024-07Clark, C., Barzegar Behrooz, A., Cordani, M., Shojaei, S., Ghavami, S. (2024). Assessing Autophagy Flux in Glioblastoma Temozolomide Resistant Cells. In: Turksen, K. (eds) Autophagy in Development and Disease. Methods in Molecular Biology, vol 2879. Humana, New York, NY. https://doi.org/10.1007/7651_2024_571978107164267297810716426891064-374510.1007/7651_2024_571https://hdl.handle.net/20.500.14352/119827Funding: M.C. is supported by grant RYC2021-031003I funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and by European Union NextGenerationEU/PRTR.Autophagy is a critical cellular process involved in the degradation and recycling of cytoplasmic components, playing a dual role in cancer by either promoting cell survival or facilitating cell death. In glioblastoma (GB), autophagy has been implicated in resistance to the chemotherapeutic agent temozolomide (TMZ). This study presents a novel method to accurately measure autophagy flux in TMZ-resistant glioblastoma cells, combining advanced imaging techniques with biochemical assays. By quantifying key autophagy markers such as LC3-II and SQSTM1, our approach provides detailed insights into the dynamic processes of autophagosome formation and clearance under therapeutic stress. This method advances our understanding of autophagy in GB chemoresistance and has significant implications for the development of autophagy-targeted therapies. The ability to monitor and manipulate autophagy flux in real time offers a promising avenue for monitoring and understanding TMZ resistance and improving patient outcomes in glioblastoma treatment.engbook part1940-6029https://doi.org/10.1007/7651_2024_571https://link.springer.com/protocol/10.1007/7651_2024_571metadata only access576616-006.04Autophagy fluxGlioblastomaLC3-IISQSTM1 degradationTemozolomide resistanceBiología celular (Biología)Oncología2407 Biología Celular3207.13 Oncología